← Back to Search

Monoclonal Antibodies

Mepolizumab for Chronic Rhinosinusitis with Nasal Polyps

Vancouver, Canada
Phase 4
Waitlist Available
Research Sponsored by St. Paul's Sinus Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be >=19 of age at the time of signing the informed consent form
Asthma diagnosis based on consistent clinical symptoms (History of wheeze, cough and breathlessness) and reversible airflow obstruction (Spirometry)
Must not have
Diagnosed or suspected malignant or premalignant nasal disease (e.g: Schniderian Papilloma, unilateral nasal polyposis)
Fungal rhinosinusitis (CT/Histology), positive Aspergillus skin prick testing and/or positive Aspergillus IgE RAST testing
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 30
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
No Placebo-Only Group

Summary

This trial aims to study how a new drug, mepolizumab, affects inflammation in the nose and head in people with chronic rhinosinusitis.

See full description
Who is the study for?
Adults diagnosed with chronic rhinosinusitis and nasal polyps, who have asthma symptoms and reversible airflow obstruction. They must be on a surgery waitlist for over 6 months, without other sinonasal diseases or severe allergies to monoclonal antibodies. Pregnant women, those with certain infections or immune conditions, severe heart failure, recent major organ transplants, or participation in other trials are excluded.Check my eligibility
What is being tested?
The trial is testing Mepolizumab's effect on patients with chronic rhinosinusitis and nasal polyps by blocking IL-5 protein involved in inflammation. It uses advanced genetic 'barcoding' (Single-cell RNA sequencing) to study individual cells' response to treatment.See study design
What are the potential side effects?
Mepolizumab may cause side effects such as headache, injection site reactions (pain, redness), fatigue, back pain and allergic reactions including anaphylaxis. The severity of these side effects can vary from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 19 years old or older.
 show original
Select...
I have asthma diagnosed with symptoms like wheezing and confirmed by a breathing test.
 show original
Select...
I have never had sinus or lower airway disease.
 show original
Select...
I am 19 years or older and can sign a consent form.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have or might have a serious nasal condition, like a tumor or severe polyps.
 show original
Select...
I have been diagnosed with fungal sinusitis and tested positive for Aspergillus.
 show original
Select...
I am managing an infection that is not related to CRS.
 show original
Select...
I am currently being treated for a long-term infection.
 show original
Select...
I have received treatments that modify my immune system.
 show original
Select...
I have an infection that is not due to long-term sinus issues.
 show original
Select...
I have tumors in my nasal cavity.
 show original
Select...
I have had a major organ or bone marrow transplant.
 show original
Select...
I have received monoclonal antibody therapy before.
 show original
Select...
I have had surgery for sinus issues or to remove nasal polyps.
 show original
Select...
I am not pregnant, planning to become pregnant, or breastfeeding during the trial.
 show original
Select...
I have EGPA with positive MPO ANCA or more than 10% eosinophils in my blood.
 show original
Select...
I was hospitalized for an infection treated with IV or IM antibiotics within the last 60 days.
 show original
Select...
I do not have severe heart failure or uncontrolled heart disease.
 show original
Select...
I have a genetic condition affecting my breathing or sinuses.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 30 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Endotyping nasal response to Mepolizumab
Nasal immune endotyping

Side effects data

From 2023 Phase 4 trial • 100 Patients • NCT04276233
5%
Pyrexia
3%
Oropharyngeal pain
3%
Headache
2%
Asthma
1%
Road traffic accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
Mepolizumab 100 mg SC

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: TreatmentExperimental Treatment1 Intervention
20 subjects with CRSwNP and asthma that will start Mepolizumab treatment
Group II: Disease control groupActive Control1 Intervention
10 subjects with CRSsNP without asthma that will not start Mepolizumab and will continue their standard of care treatment.
Group III: Control groupActive Control1 Intervention
10 healthy subjects without any sinuses disease
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mepolizumab
2020
Completed Phase 4
~5010

Find a Location

Closest Location:St. Paul's Sinus Centre· Vancouver, Canada· 2050 miles
Image of St. Paul's Sinus Centre in Vancouver, Canada.Image of St. Paul's Sinus Centre in Vancouver, Canada.Image of St. Paul's Sinus Centre in Vancouver, Canada.

Who is running the clinical trial?

St. Paul's Sinus CentreLead Sponsor
3 Previous Clinical Trials
130 Total Patients Enrolled
~25 spots leftby Jan 2026